FDA Approves Human Genome Drug (HGSI)

The FDA has voted 10-5 in favor of approving Human Genome Sciences HGSI Benlysta, saying the drug is effective in treatment. Shares were halted all day, before the announcement of the panel's recommendation. The last trade for HGSI was $25.88. Human Genome Sciences Inc. has drugs in its pipeline that include novel drugs to treat hepatitis C, lupus, inhalation anthrax, and cancer.